Inventor · disambiguated record
Julien Lefranc
Also filed as: LEFRANC JULIEN
9 granted patents·3 pending applications·47 citations·filing 2015–2022
85Inventor score
Top patents by PatentIndex Score
12 records- 0196US9549932B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2016·Granted Jan 24, 2017·26 cites·30 claims
- 0293US10729680B25-substituted 2-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2017·Granted Aug 4, 2020·10 cites·14 claims
- 0389US9993484B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2015·Granted Jun 12, 2018·4 cites·9 claims
- 0485US11529356B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2020·Granted Dec 20, 2022·1 cites·20 claims
- 0585US10772893B22-(morpholin-4-yl)-1,7-naphthyridinesBayer Pharma AG·Filed 2018·Granted Sep 15, 2020·2 cites·12 claims
- 0678US11304946B22-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor antagonistsBAYER AG·Filed 2018·Granted Apr 19, 2022·2 cites·11 claims
- 0768US11524944B22-phenylpyrimidine-4-carboxamides as AHR inhibitorsBAYER AG·Filed 2018·Granted Dec 13, 2022·1 cites·11 claims
- 0866US10487092B2Pyrazolopyridinamines as MKNK1 and MKNK2 inhibitorsBayer Pharma AG·Filed 2015·Granted Nov 26, 2019·1 cites·22 claims
- 0954US2024174683A1Map4k1 inhibitorsBAYER AG·Filed 2022·Application pending·0 cites
- 1048US2023062100A1Substituted aminoquinolones as dgkalpha inhibitors for immune activationBAYER AG·Filed 2020·Application pending·0 cites
- 1148US2023113037A1[1,2,4]triazolo[1,5-c]quinazolin-5-aminesBAYER AG·Filed 2020·Application pending·0 cites
- 1240US10894784B2Heteroarylbenzimidazole compoundsBayer Pharma AG·Filed 2016·Granted Jan 19, 2021·0 cites·15 claims
Join the waitlist — get patent alerts
Get an alert when Julien Lefranc files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →